Fate Therapeutics Inc (OQ:FATE)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 12278 Scripps Summit Drive
SAN DIEGO CA 92131
Tel: N/A
Website: https://fatetherapeutics.com
IR: See website
<
Key People
John Scott Wolchko
President, Chief Executive Officer, Director
Edward J. Dulac
Chief Financial Officer
Cindy R. Tahl
General Counsel and Corporate Secretary
Brian T. Powl
Chief Commercial Officer
Bahram Valamehr
Chief Research and Development Officer
 
Business Overview
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company's platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Financial Overview
For the fiscal year ended 31 December 2023, Fate Therapeutics Inc revenues decreased 34% to $63.5M. Net loss decreased 43% to $160.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research & Development decrease of 44% to $151.7M (expense), Stock-based Compensation in R&D decrease of 59% to $20.8M (expense).
Employees: 181 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $122.81M as of Dec 31, 2023
Annual revenue (TTM): $63.53M as of Dec 31, 2023
EBITDA (TTM): -$172.23M as of Dec 31, 2023
Net annual income (TTM): -$160.93M as of Dec 31, 2023
Free cash flow (TTM): -$138.42M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 113,172,530 as of Mar 19, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.